



“*Health cannot be a question of income; it is a fundamental human right.*”

# Health is Critical to Human Development & Access to Medicines and Vaccines is an Essential part of UHC

- Many international treaties and governments all over the world recognize health as a fundamental human right and ACCESS to MEDICINES & VACCINES has been accepted as part of the right to health (ICESCR, 2000)
- Enhancing **access to existing essential medicines and vaccines** could potentially save 10million lives annually, most of whom live in developing countries of Africa and Asia (WHO, 2004).
- **SDG Target 3.8:** *“access to safe, effective, quality and affordable essential medicines and vaccines for all”* is a vital part of Universal Health Coverage (UN, 2015)

Vaccines are a cost-effective healthcare intervention with significant economic impact

**For every  
\$1 spent**

on immunization ...

**\$16**

healthcare impact -  
reduction in morbidity  
and mortality<sup>1</sup>

**\$44**

broader economic and  
social benefits


<sup>1</sup> Average return on investment (cost of illness, treatment, loss of productivity etc) for low and middle income countries till 2020 (range: 9.78- 24.91)



*“Vaccines are the tugboats of preventive health”* -William Foote

- Company Overview
- BVNL Approach
- Advancing Vaccines Development in Africa
- Challenges
- Future Plans, AVMI role...

## Company Overview



Support NPHCDA in Achieving GVAP Goals in Nigeria & the Region

- **Biovaccines Nigeria Limited (BVNL) is a Joint Venture between the Federal Government of Nigeria (FGN), and May & Baker Nigeria Plc (MBN).**
- **Incorporated in 2005 as the Special Purpose Vehicle to revive vaccines production activity in the country.**
- **The company is owned 51 per cent by MBN. and 49 per cent by the FGN**
- **Re-inauguration of Board in January 19, 2018**

## Company Overview contd

### Vision

*To be a trusted ally in immunization in Africa.*

### Mission


*To accelerate disease control, protect and support human health; through research and development, and manufacturing of essential and novel vaccines.*

### Objectives

- ❖ To produce safe and affordable human vaccines for Nigeria, create a regional centre for vaccine production in West Africa and reverse the situation of high mortality from vaccine preventable diseases;
- ❖ To develop local skills base/capacity in vaccines production and testing as well as carry out Research and Development (R&D) to develop vaccines against Africa specific antigens; and
- ❖ To support the Nigerian economy through job creation, immunization cost savings and foreign exchange earnings from export to other markets.
- ❖ To position Nigeria as a global player in Vaccine Business


# NIGERIA-Large and Growing Population

Total population (2017)	191,835,907
Birth cohort (2017)	7,322,279
Surviving Infants (surviving to 1 year per year, 2017)	6,822,481
Infant mortality rate (deaths < 1 year per 1000 births, 2015)	69/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015)	109/1000
World Bank Index, IDA (2015)	3.41
Gross Nation Income (per capita US\$, 2015)	2,820
Co-financing group (2017)	Accelerated transition
No. of districts/territories (2016)	774



Population growth in China, India, Nigeria and USA


1950-2100, actual and projected




Source: United Nations

<http://www.gavi.org/country/nigeria/documents/>


## Shifting Disease Pattern



## Distribution of Under-Five Deaths By Cause



# Nigeria depends 100% on imports of Vaccines and is in Accelerated GAVI Transition



**These vaccines can save 4.6 million lives from vaccine preventable diseases over the next 10 years**

**4.6 million**  
 Deaths of Nigerian children averted from vaccine preventable diseases

*Vaccine preventable diseases cause significant morbidity including deafness, impaired learning and other disabilities*

**Nigeria has to manufacture its own vaccines, If NOT now then When ?**

## BVNL Approach-Business Model

- ROI-TAT

- Priority Status for Nigeria & Region

- Demand Supply Gap (No of manufacturers)


- Dedicated Vs Campaign ability to Maximize output

- Manufacturing Platform Conventional Vs Contemporary



## BVNL Approach-Business Model

Forward Integration



Backward Integration



Forward Integration by setting up a lab for basic research & development of vaccines for regional diseases such as Lassa, Listeriosis, Monkey Pox etc

Backward Integration by setting up a Formulation filling facility for Established Vaccines in Routine immunization



## Challenges-the road ahead

- Long
- Challenging
  
- Navigable
- Possible



- Rapidly changing immunization landscape
- NRA & NCL
- Technical Talent
- Full Green Field
- Funding
- Perception on possibility


## Future Plans/AVMI Action

- TBI, Feb, 2018 - *Knowledge, Information & Experience Gathering visit* AVMI to promote more of such exchanges
- AVMI to metamorphose into a Network— *Manage competition, encourage knowledge sharing, capacity development*
- Talent Development
- Advocacy - National African Governments
  - Politics-Science-Business
  - Communique in National dailies

**When your ambition is big  
Then your efforts should be even bigger**



From Concept



To Commercialization



**TOGETHER WE CAN ACHIEVE IT !**





**A 'NICE' - *Thank You***  
**'Nigeria Immunization Coverage Enhancement' -  
Initiative**